Literature DB >> 22361040

The expression and prognostic significance of hepatoma-derived growth factor in oral cancer.

Yu-Wei Lin1, Chien-Feng Li, Hsuan-Yu Chen, Ching-Yu Yen, Li-Ching Lin, Chao-Cheng Huang, Hsuan-Ying Huang, Ping-Ching Wu, Chang-Han Chen, San-Cher Chen, Ming-Hong Tai.   

Abstract

Hepatoma-derived growth factor (HDGF) participates in oncogenic progression and represents a prognostic factor in several types of cancer. This study aimed to elucidate the role of HDGF during oral carcinogenesis. HDGF expression and the tumorigenic behaviors in human oral cell lines were investigated by immunoblotting, invasion and colony formation assays. Recombinant adenovirus vectors were employed to modulate the HDGF level in oral cancer cells. Immunohistochemical analysis using tissue microarray (TMA) consisting of surgically resected samples from 95 oral cancer patients was performed to delineate the correlation between HDGF expression and clinic-pathological parameters. HDGF expression was higher in malignant oral cancer cells than benign ones. Adenovirus-mediated HDGF overexpression and knockdown demonstrated the cellular HDGF level regulated the tumorigenic behaviors of oral cancer cells. Immunohistochemical analysis revealed increased HDGF expression in the nucleus and cytoplasm in oral cancer tissues. The nuclear HDGF expression was significantly correlated with tumor stage (P=0.004) and grade (P=0.013) while the cytoplasmic HDGF expression was associated with tumor necrosis (P=0.002). Kaplan-Meier analysis revealed that patients with high nuclear HDGF expression had significantly worse 5-year disease-specific survival (P=0.0069), metastasis-free survival (P=0.0168), and local recurrence-free survival (P=0.0047). Multivariate analysis indicated that the nuclear HDGF labeling index was an independent prognostic factor for disease-specific and local recurrence-free survival. HDGF overexpression contributes to the oncogenic processes in oral cancer cells and constitutes a novel prognostic factor for survival outcome of oral cancer patients.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22361040     DOI: 10.1016/j.oraloncology.2012.01.014

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  12 in total

1.  Upregulation of nucleus HDGF predicts poor prognostic outcome in patients with penile squamous cell carcinoma bypass VEGF-A and Ki-67.

Authors:  Dawei Li; Zhen Han; Jikai Liu; Xiang Zhang; Juchao Ren; Lei Yan; Hainan Liu; Zhonghua Xu
Journal:  Med Oncol       Date:  2013-09-03       Impact factor: 3.064

2.  Downregulated expression of hepatoma-derived growth factor (HDGF) reduces gallbladder cancer cell proliferation and invasion.

Authors:  Maolan Li; Jun Shen; Xiangsong Wu; Bingtai Zhang; Rui Zhang; Hao Weng; Qian Ding; Zhujun Tan; Guofeng Gao; Jiasheng Mu; Jiahua Yang; Yijun Shu; Runfa Bao; Qichen Ding; Wenguang Wu; Yang Cao; Yingbin Liu
Journal:  Med Oncol       Date:  2013-04-23       Impact factor: 3.064

3.  The interaction of hepatoma-derived growth factor and β-catenin promotes tumorigenesis of synovial sarcoma.

Authors:  Jianming Tang; Huijuan Shi; Hui Li; Tiantian Zhen; Yu Dong; Fenfen Zhang; Yang Yang; Anjia Han
Journal:  Tumour Biol       Date:  2016-02-02

4.  Prognostic significance of nuclear hepatoma-derived growth factor expression in gallbladder cancer.

Authors:  Feng Tao; Min-Feng Ye; Ai-Jing Sun; Jie-Qing Lv; Guan-Gen Xu; Yuan-Ming Jing; Wei Wang
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

5.  The expression and clinical significance of HDGF in osteosarcoma.

Authors:  Zhiguo Chen; Shenghai Qiu; Xiaofei Lu
Journal:  Onco Targets Ther       Date:  2015-09-09       Impact factor: 4.147

6.  Hepatoma-derived growth factor/nucleolin axis as a novel oncogenic pathway in liver carcinogenesis.

Authors:  San-Cher Chen; Tsung-Hui Hu; Chao-Cheng Huang; Mei-Lang Kung; Tian-Huei Chu; Li-Na Yi; Shih-Tsung Huang; Hoi-Hung Chan; Jiin-Haur Chuang; Li-Feng Liu; Han-Chung Wu; Deng-Chyang Wu; Min-Chi Chang; Ming-Hong Tai
Journal:  Oncotarget       Date:  2015-06-30

7.  Domain swapping and SMYD1 interactions with the PWWP domain of human hepatoma-derived growth factor.

Authors:  Li-Ying Chen; Yen-Chieh Huang; Shih-Tsung Huang; Yin-Cheng Hsieh; Hong-Hsiang Guan; Nai-Chi Chen; Phimonphan Chuankhayan; Masato Yoshimura; Ming-Hong Tai; Chun-Jung Chen
Journal:  Sci Rep       Date:  2018-01-10       Impact factor: 4.379

8.  Downregulated expression of hepatoma-derived growth factor inhibits migration and invasion of prostate cancer cells by suppressing epithelial-mesenchymal transition and MMP2, MMP9.

Authors:  Feilong Yang; Nengwang Yu; Hui Wang; Cong Zhang; Zhao Zhang; Yanxiang Li; Dawei Li; Lei Yan; Hainan Liu; Zhonghua Xu
Journal:  PLoS One       Date:  2018-01-04       Impact factor: 3.240

9.  The evaluation of hepatoma-derived growth factor in determining of prognosis and estimating of invasive probability of tumoral cells, recurrent, and metastasis of lymphatic glands in breast carcinoma.

Authors:  Behrang Kazeminezhad; Behdad Baradaran; Mohammad Reza Hafezi Ahmadi
Journal:  J Family Med Prim Care       Date:  2017 Oct-Dec

10.  Hepatoma-derived growth factor functions as an unfavorable prognostic marker of human gliomas.

Authors:  Yang Yang; Shengru Liang; Yuqian Li; Fei Gao; Longlong Zheng; Shilai Tian; Pu Yang; Lihong Li
Journal:  Oncol Lett       Date:  2017-10-13       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.